Amylyx Pharmaceuticals (AMLX) Q1 2026 earnings summary

Executive summary

• Completed enrollment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH; topline data expected Q3 2026, with NDA preparations and potential commercial launch in 2027 if approved.

• Initiated Expanded Access Program for avexitide in PBH to address urgent patient need.

• Advanced pipeline: AMX0318 (IND-enabling studies, milestone payment to Gubra), AMX0035 (positive Phase 2 in Wolfram syndrome, week 96 data upcoming), AMX0114 (ALS trial ongoing, Cohort 2 enrolled, biomarker data expected in June).

• Cash runway projected to fund operations through potential avexitide commercialization and into 2028.

• Clinical-stage pharmaceutical company focused on therapies for endocrine and neurodegenerative diseases, with four investigational therapies in development.

Financial highlights

• Ended Q1 2026 with $279.8 million in cash and marketable securities, down from $317 million at end of Q4 2025.

• Net loss for Q1 2026 was $41.3 million ($0.37/share), a 15% increase from $35.9 million ($0.42/share) in Q1 2025.

• Total operating expenses were $43.8 million, up 16% year-over-year.

• R&D expenses rose to $27.6 million from $22.1 million, mainly due to avexitide clinical development and $4 million milestone payment to Gubra for AMX0318.

• Selling, general, and administrative expenses increased to $16.2 million, reflecting commercial launch preparations and higher consulting/professional services.

Outlook and guidance

• Cash runway expected into 2028, supporting key milestones including LUCIDITY readout, potential FDA approval, and commercial launch of avexitide in 2027.

• Topline data for avexitide Phase 3 LUCIDITY trial expected in Q3 2026.

• IND filing for AMX0318 targeted for 2027.

• Anticipated presentation of AMX0035 week 96 data and AMX0114 biomarker data in upcoming scientific meetings.